Saragovi HU - Search Results

1

Aiming for the Sweet Spot: Glyco-Immune Checkpoints and γδ T Cells in Targeted Immunotherapy.

Bartish M, Del Rincón SV, Rudd CE, Saragovi HU. Bartish M, et al. Among authors: saragovi hu. Front Immunol. 2020 Sep 29;11:564499. doi: 10.3389/fimmu.2020.564499. eCollection 2020. Front Immunol. 2020. PMID: 33133075 Free PMC article. Review.

2

Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.

Huang F, Gonçalves C, Bartish M, Rémy-Sarrazin J, Issa ME, Cordeiro B, Guo Q, Emond A, Attias M, Yang W, Plourde D, Su J, Gimeno MG, Zhan Y, Galán A, Rzymski T, Mazan M, Masiejczyk M, Faber J, Khoury E, Benoit A, Gagnon N, Dankort D, Journe F, Ghanem GE, Krawczyk CM, Saragovi HU, Piccirillo CA, Sonenberg N, Topisirovic I, Rudd CE, Miller WH Jr, Del Rincón SV. Huang F, et al. Among authors: saragovi hu. J Clin Invest. 2021 Apr 15;131(8):e140752. doi: 10.1172/JCI140752. J Clin Invest. 2021. PMID: 33690225 Free PMC article.

3

Effective chimeric antigen receptor T cells against SARS-CoV-2.

Guo X, Kazanova A, Thurmond S, Saragovi HU, Rudd CE. Guo X, et al. Among authors: saragovi hu. iScience. 2021 Nov 19;24(11):103295. doi: 10.1016/j.isci.2021.103295. Epub 2021 Oct 16. iScience. 2021. PMID: 34693218 Free PMC article.

4

Vaccination with Tumor-Ganglioside Glycomimetics Activates a Selective Immunity that Affords Cancer Therapy.

Tong W, Maira M, Roychoudhury R, Galan A, Brahimi F, Gilbert M, Cunningham AM, Josephy S, Pirvulescu I, Moffett S, Saragovi HU. Tong W, et al. Among authors: saragovi hu. Cell Chem Biol. 2019 Jul 18;26(7):1013-1026.e4. doi: 10.1016/j.chembiol.2019.03.018. Epub 2019 May 16. Cell Chem Biol. 2019. PMID: 31105061 Free article.

5

Neuroprotection: Pro-survival and Anti-neurotoxic Mechanisms as Therapeutic Strategies in Neurodegeneration.

Saragovi HU, Galan A, Levin LA. Saragovi HU, et al. Front Cell Neurosci. 2019 Jun 6;13:231. doi: 10.3389/fncel.2019.00231. eCollection 2019. Front Cell Neurosci. 2019. PMID: 31244606 Free PMC article. Review.

6

Novel approaches for targeted cancer therapy.

Guillemard V, Saragovi HU. Guillemard V, et al. Among authors: saragovi hu. Curr Cancer Drug Targets. 2004 Jun;4(4):313-26. doi: 10.2174/1568009043332989. Curr Cancer Drug Targets. 2004. PMID: 15180497 Review.

7

Signal transduction and antiproliferative function of the mammalian receptor for type 3 reovirus.

Saragovi HU, Rebai N, Roux E, Gagnon M, Zhang X, Robaire B, Bromberg J, Greene MI. Saragovi HU, et al. Curr Top Microbiol Immunol. 1998;233(Pt 1):155-66. doi: 10.1007/978-3-642-72092-5_7. Curr Top Microbiol Immunol. 1998. PMID: 9599925 Review. No abstract available.

8

HER2-mediated internalization of a targeted prodrug cytotoxic conjugate is dependent on the valency of the targeting ligand.

Guillemard V, Nedev HN, Berezov A, Murali R, Saragovi HU. Guillemard V, et al. Among authors: saragovi hu. DNA Cell Biol. 2005 Jun;24(6):350-8. doi: 10.1089/dna.2005.24.351. DNA Cell Biol. 2005. PMID: 15941387

9

Ligands Binding to Cell Surface Ganglioside GD2 Cause Src-Dependent Activation of N-Methyl-D-Aspartate Receptor Signaling and Changes in Cellular Morphology.

Tong W, Maira M, Gagnon M, Saragovi HU. Tong W, et al. Among authors: saragovi hu. PLoS One. 2015 Aug 7;10(8):e0134255. doi: 10.1371/journal.pone.0134255. eCollection 2015. PLoS One. 2015. PMID: 26252487 Free PMC article.

10

A cell cycle regulating receptor is localized on cell surface and in nuclei of mitotically and meiotically dividing cells.

Roux E, Robaire B, Saragovi HU. Roux E, et al. Among authors: saragovi hu. DNA Cell Biol. 1998 Mar;17(3):239-47. doi: 10.1089/dna.1998.17.239. DNA Cell Biol. 1998. PMID: 9539104

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

132 results

Search Page